Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma
It is becoming clear that myeloma cell-induced disruption of the highly organized bone marrow components (both cellular and extracellular) results in destruction of the marrow and support for multiple myeloma (MM) cell proliferation, survival, migration, and drug resistance. Since the first phase I...
Main Authors: | Mariah L. Farrell, Michaela R. Reagan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-05-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fendo.2018.00218/full |
Similar Items
-
Proteasome Inhibitors for the Treatment of Multiple Myeloma
by: Shigeki Ito
Published: (2020-01-01) -
New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01) -
Development and characterization of three cell culture systems to investigate the relationship between primary bone marrow adipocytes and myeloma cells
by: Heather Fairfield, et al.
Published: (2023-01-01) -
Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment
by: Cassidy M. Van Stiphout, et al.
Published: (2022-09-01) -
The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia
by: Chun-fung Sin, et al.
Published: (2021-12-01)